title: Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQO1 609C-->T mutation and rapid fractional excretion of chlorzoxazone.
abstract: Benzene is a ubiquitous occupational hematotoxin and leukemogen, but people vary in their response to this toxic agent. To evaluate the impact of interindividual variation in enzymes that activate (i.e., CYP2E1) and detoxify (i.e., NQO1) benzene and its metabolites, we carried out a case-control study in Shanghai, China, of occupational benzene poisoning (BP; i.e., hematotoxicity), which we show is itself strongly associated with subsequent development of acute nonlymphocytic leukemia and the related myelodysplastic syndromes (relative risk, 70.6; 95% confidence interval, 11.4-439.3). CYP2E1 and NQO1 genotypes were determined by PCR-RFLP, and CYP2E1 enzymatic activity was estimated by the fractional excretion of chlorzoxazone (fe(6-OH)) for 50 cases of BP and 50 controls. Subjects with both a rapid fe(6-OH). and two copies of the NQO1 609C-->T mutation had a 7.6-fold (95% confidence interval, 1.8-31.2) increased risk of BP compared to subjects with a slow fe(6-OH) who carried one or two wild-type NQO1 alleles. In contrast, the CYP2E1 PstI/RsaI polymorphism did not influence BP risk. This is the first report that provides evidence of human susceptibility to benzene-related disease. Further evaluation of susceptibility for hematotoxicity and hematological malignancy among workers with a history of occupational exposure to benzene is warranted.
authors.affiliation: Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA.
authors.forename: N
authors.initials: N
authors.lastname: Rothman
authors.forename: M T
authors.initials: MT
authors.lastname: Smith
authors.forename: R B
authors.initials: RB
authors.lastname: Hayes
authors.forename: R D
authors.initials: RD
authors.lastname: Traver
authors.forename: B
authors.initials: B
authors.lastname: Hoener
authors.forename: S
authors.initials: S
authors.lastname: Campleman
authors.forename: G L
authors.initials: GL
authors.lastname: Li
authors.forename: M
authors.initials: M
authors.lastname: Dosemeci
authors.forename: M
authors.initials: M
authors.lastname: Linet
authors.forename: L
authors.initials: L
authors.lastname: Zhang
authors.forename: L
authors.initials: L
authors.lastname: Xi
authors.forename: S
authors.initials: S
authors.lastname: Wacholder
authors.forename: W
authors.initials: W
authors.lastname: Lu
authors.forename: K B
authors.initials: KB
authors.lastname: Meyer
authors.forename: N
authors.initials: N
authors.lastname: Titenko-Holland
authors.forename: J T
authors.initials: JT
authors.lastname: Stewart
authors.forename: S
authors.initials: S
authors.lastname: Yin
authors.forename: D
authors.initials: D
authors.lastname: Ross
mesh_terms: D001554:Benzene / Q000506:poisoning*; D002753:Chlorzoxazone / Q000378:metabolism*; D015331:Cohort Studies; D019392:Cytochrome P-450 CYP2E1 / Q000235:genetics; D019337:Hematologic Neoplasms / Q000139:chemically induced*; D006801:Humans; D009154:Mutation; D016660:NAD(P)H Dehydrogenase (Quinone) / Q000235:genetics; D016273:Occupational Exposure / Q000009:adverse effects*; D012189:Retrospective Studies; D012307:Risk Factors
chemical_list: D019392:Cytochrome P-450 CYP2E1; D016660:NAD(P)H Dehydrogenase (Quinone); D002753:Chlorzoxazone; D001554:Benzene